Our team is composed of experts in the field of life sciences and a trach record in Biotech Companies
Founders & Management Team
Co-Founder and Advisor
PhD in biochemistry at Universitat Autonoma de Barcelona (UAB). He has worked in biomedical research for more than 25 years, 20 of them in the study of cancer, specifically sarcomas, mainly in children. He has published 28 articles in international journals and experience in clinical trials design (Phase I and II). In addition, he has produced an international guideline for the treatment of patients with resistant sarcomas. He is the co-Founder of Aptadel Therapeutics and also the group leader of Sarcoma’s group at the Biomedical research institute IDIBELL (Spain).
Chief Scientific Ofiicer
PhD in Biomedicine at Universitat de Barcelona (UB). She has got international experience as a scientist 10+ years in cancer biomedical research with several publications. She has got 7+ years experience in innovation and technology transfer. Gisela has worked at Medipex Ltd., a healthcare innovation HUB to connect the NHS with industry and academia in the UK. She has also been head of the Innovation portfolio and Tech Transfer Department at the biomedicine research institute IDIBELL (Spain) for 5 years.
PhD in Biochemistry at University of Oxford and MBA at Harvard Business School . He is co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. He founded successful biotech companies in Barcelona, Boston and Zürich as CEO and he is Board Member/Advisor multiple early-stage biotech companies (EU/US).
PhD in Molecular Oncology at CNIO and executive education at ESADE Business School. He has got a scientific track-record as author/co-author of 16 articles. Gonzalo is partner at Chasing Science, a Barcelona-based biomedical venture builder and CSO at the Biotech company Ninevah Therapeutics.
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine, located in the south of Barcelona, promoted by the Bellvitge University Hospital and Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.
IDIBELL research is focused in cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the axes on which researchers work every day with the goal of improving the quality of life of citizens.
Fundación Alba Pérez
The Alba Perez Foundation is a Spanish foundation that aims to raise funds for the creation of scholarships, grants and/or contracts or collaboration agreements with both public and private entities for research in the fight against childhood cancer, and in particular, Ewing’s Sarcoma.
It is dedicated to the organisation, implementation and management of promotional events, dissemination, fundraising through donations from individuals, public bodies and companies in order to devote these funds to research into childhood cancers.
Aptamer Development Advisor
PhD in Pharmacology and Cancer Biology at Duke University. She is an Associate Professor at the University of Iowa and has been Director of Research at Moderna Therapeutics. She is an internationally recognized expert in oligonucleotide therapeutics and delivery. She has 60+ publications/9+ patents related to the development of novel RNA-based therapies for many diseases.
Juan Martín Liberal
PhD in Biomedicine at University of Barcelona. He is an experienced medical and consultant oncologist at Catalan Institut of Oncology (ICO). Juan has worked as Clinical Investigator at Early Drug Development and Molecular Therapy in Cancer. He has also wide experience in Clinical Trials, specially for Sarcomas.